Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Kimberly Lee who wrote (2096)	4/16/1999 3:56:00 PM
From: Jeffrey L. Henken	Read Replies (2) \| Respond to of 108040

Good sized spread on USAB. Careful might be a limit order? Thanks, Jeff

To: Kimberly Lee who wrote (2096)	4/16/1999 10:14:00 PM
From: Silver Knife	Respond to of 108040

Kimberly, Do you still like MRPS? They had a late afternoon news release announcing a first quarter profit and closed up 7/16. quote.yahoo.com SK

To: Kimberly Lee who wrote (2096)	4/16/1999 10:18:00 PM
From: ynot	Respond to of 108040

Kimberly, do you or xr560 (?) have a feeling for lpgly? Don't watch TV but saw some INVESTMENT show at the in-laws about CMGI swinging 100 points today and MR DAYTRADER saying 'geeze caught it at the bottom as usual' :P Is it even considered in the same league 'on the street'? Thanks ynot :)

To: Kimberly Lee who wrote (2096)	4/16/1999 11:02:00 PM
From: HEMIGUY	Read Replies (1) \| Respond to of 108040

I am new to this thread and have enjoyed your collaboration with each other. The professionalism of this group is hard to find on just any group... Kim right now I own a few stocks I've seen this group talk about. What are you opinions of these. TNRG, LPGLY, MRPS. Thanks again and looking forward for all the concise information.

To: Kimberly Lee who wrote (2096)	4/17/1999 11:55:00 AM
From: SteelerStu	Respond to of 108040

Kim -- WASP - pharmaceutical company selling for $2 just received $25 million in funding for revolutionary ACNE treatment -- Major PRs due over the next few weeks involving contracts etc... -- This is picking up steam and will be a high flier guaranteed -- float is between 1.5 and 3.5 million -- lots of info on Raging Bull -- looking for $15-$20 within 1 month from $2 today ragingbull.com ragingbull.com Message 8977558 Thanks for KYOM - should be a good week or two -- anything is better than the last two days --- LOL

To: Kimberly Lee who wrote (2096)	4/17/1999 12:55:00 PM
From: SteelerStu	Respond to of 108040

WASP - Monday April 12, 12:38 pm Eastern Time Company Press Release Cystic Acne Study Brings Dramatic Results MIDVALE, Utah--(BUISNESS WIRE)--April 12, 1999--Wasatch Pharmaceutical Inc. (OTC BB:WASP - news) has previously announced clinical trials, and the treatment of acne patients in a clinical setting under the direction and cooperation of a major pharmaceutical research entity, and approximately 250 physicians. With several thousand patients having been treated, Wasatch has announced a success rate of 95% with virtually no side effects. Success is interpreted as total or near total eradication of both cystic acne and the less serious grades of acne. This product is used topically, and is far superior to anything now being used by prescription or in the over-the-counter market. With the success of this therapy, entry into the retail market has been solicited by an independent distributor representing eighteen hundred pharmacies. In addition, two major retail chains representing over 30% of the over-the-counter market are accessible through relationships presently representing Wasatch Pharmaceutical. The acne market is a $3 Billion market and with a superior product, Wasatch will aggressively penetrate and control a significant share of this market. This press release contains forward-looking statements regarding Wasatch Pharmaceutical Inc. and its future sales-related activities. Actual results could differ materially from those described or implied in this press release as a result of a number of factors. These include, but are not limited to, the future growth of these markets, any adverse actions by the companys partners, competitive products, other economic factors affecting the companys markets, the degree of acceptance that new products achieve, and seasonal changes. Readers are referred to public documents filed by Wasatch Pharmaceutical, Inc. with the Securities and Exchange Commission which identify important risk factors that could cause actual results to differ from those contained in any forward-looking statements. Contact: Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709